Fig 1: Demographic, clinical and immunological status of 18 pediatric patients with Kawasaki disease or MIS-C(A) Cumulative SARS-CoV-2 positive cases identified by PCR testing within the Birmingham area compared to MIS-C cases admitted to Birmingham Children's Hospital PICU.(B) Age of KD and MIS-C patients recruited to this study.(C) Clinical laboratory results shown for C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, troponin, and vitamin D.(D) Disease severity indicators shown as days hospitalized, days in PICU and treatment cycles of IVIG, intravenous steroids, and Tocilizumab.(E) Pretreatment absolute count of different immune cell subsets expressed as 109 cells/L.(F) Left: Principal component analysis biplot of clinical laboratory features for patients with MIS-C or KD and synthetic healthy controls derived from normal range data. Right: Loading plot showing the top 7 features contributing to principal components one and two.(G) Correlation matrix of clinical features, immune parameters and demographics for the 16 MIS-C patients. The strength of each correlation is indicated by color and statistical significance by asterisks: ∗p < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. Black outline indicates a significant result after 5% false discovery rate correction using the Benjamini-Hochberg method.(H) Pretreatment frequency of lymphocyte subsets expressed as the absolute number of cells x109/L (left column) or percentage of total lymphocytes (right column).(I) SARS-CoV-2 ab responses for IgM, IgA, and IgG. In panels C, E, and H the normal range for each patient, based on their age, is shown by the vertical dark gray bar. Data points outside the normal range are drawn with a black outline.See also Figure S1.